Neuland Laboratories Limited (NEULANDLAB) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Neuland Laboratories Limited ₹5,987, price ₹21,505, upside -72.2%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Neuland Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹961.69 – ₹23,995 · fair‑value band ₹4,191 – ₹7,783 · the ₹21,505 price screens above the ₹5,987 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Neuland Laboratories in your weekly email
Every Wednesday you see whether Neuland Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Stock analysis
Neuland Laboratories Limited (NEULANDLAB) currently trades at ₹21,505, while our model-based Fair Value estimate is ₹5,987, 72.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹5,987 per share, and 0 of the 17 models we run sit above the ₹21,505 price.
Bear case: the Asset-Based group reads lowest at ₹978.88, and 17 of the 17 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹4,191 (bear) to ₹7,783 (bull), the price of ₹21,505 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Neuland Laboratories Limited reported revenue of ₹20.2B in FY2026 versus ₹9.2B in FY2022, a compound +21.7%/yr. Reported net income was ₹3.6B in FY2026, compounding +54.5%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹276B (≈ $2.9B) · P/E ratio 55.3 · P/S ratio 9.95 · EPS (TTM) ₹389.03 · Dividend yield 0.1% · Net margin 18.0% · Return on equity 15.9% · Return on assets (EBIT) 14.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 86% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −72%, NEULANDLAB screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹181.49 to ₹9,976). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹4,191Fair Value ₹5,987Bull ₹7,783
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹198.25 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+41.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Start year 2021 (pandemic). Over 10 years: +14.8% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+41.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+41.7%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.41.7% vs 24.9%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 24%
Compare Neuland Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−72.2% · Bottom 25%
Profitability
Return on equity (TTM)15.9% · Top 25%
Return on assets7.2% · Top 25%
Net margin (TTM)21.0% · Top 25%
Operating margin (TTM)30.6% · Top 25%
Growth and dividend
Revenue growth119.2% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)55.3× · Priciest 25%
P/B14.72× · Priciest 25%
P/S (TTM)11.63× · Priciest 25%
EV/EBITDA36.3× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 17
FUTURE (revenue growth)100· sector 24
PAST (return on equity)64· sector 27
HEALTH (low debt)96· sector 96
DIVIDEND (yield)1· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Neuland Laboratories Limited (NEULANDLAB) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹5,987 versus a price of ₹21,505, about −72% upside (overvalued).
What is the fair value of NEULANDLAB?
Our model-based fair value for Neuland Laboratories Limited is ₹5,987 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹21,505.
What is the quality score of NEULANDLAB?
Neuland Laboratories Limited has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuland Laboratories Limited (NEULANDLAB)?
Our model-based price target is the fair value of ₹5,987 (as of Oct 1, 2026) from 17 valuation models. Cautious scenario ₹4,191, optimistic scenario ₹7,783. It is a calculation from audited fundamentals, not an analyst target.
What is the Neuland Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹5,987, about −72% upside versus a price of ₹21,505 (overvalued). Cautious scenario ₹4,191, optimistic scenario ₹7,783. The calculation is refreshed regularly with new filings.
What is the revenue of Neuland Laboratories Limited (NEULANDLAB)?
Neuland Laboratories Limited reported trailing-twelve-month revenue of about ₹23.7B (latest available figure, as of Oct 1, 2026).
Does Neuland Laboratories Limited pay a dividend?
Neuland Laboratories Limited currently shows a dividend yield of about 0.06% relative to its recent price (as of Oct 1, 2026).
What is the intrinsic value of Neuland Laboratories Limited (NEULANDLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuland Laboratories Limited it is ₹5,987 per share (as of Oct 1, 2026), against a price of ₹21,505. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Neuland Laboratories Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, NEULANDLAB trades above its calculated fair value: price ₹21,505, fair value ₹5,987, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NEULANDLAB?
No. The price is what the market pays today (₹21,505); the fair value is what the company's own numbers justify (₹5,987). For Neuland Laboratories Limited the two are ₹15,518 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuland Laboratories Limited worth?
The market values Neuland Laboratories Limited at about ₹276B (market capitalisation, as of Oct 1, 2026). Per share that is ₹21,505; our models calculate a fair value of ₹5,987 per share.
What do the bullish and bearish scenarios say about NEULANDLAB?
Our models span a range for Neuland Laboratories Limited: cautious scenario ₹4,191, base ₹5,987, optimistic ₹7,783 per share (as of Oct 1, 2026, price ₹21,505). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NEULANDLAB?
Neuland Laboratories Limited trades at a price-to-earnings ratio of 55.3 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5,987 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 34.4. Other multiples: P/B 14.7, P/S 11.6, EV/EBITDA 36.3.
How solid is the balance sheet of Neuland Laboratories Limited (NEULANDLAB)?
Balance-sheet figures for Neuland Laboratories Limited (as of Oct 1, 2026): return on equity 15.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is NEULANDLAB from its 52-week high?
Neuland Laboratories Limited trades at ₹21,505, about 10% below its 52-week high of ₹23,995 and 86% above the low of ₹11,534 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5,987 is for.
Which stocks are comparable to Neuland Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuland Laboratories Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹21,505, calculated fair value ₹5,987 (−72%), Quality Score 55/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NEULANDLAB calculated?
We run Neuland Laboratories Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹5,987, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Neuland Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neuland Laboratories Limited (NEULANDLAB)?
The closing price on Oct 1, 2026 was ₹21,505. Our model-based fair value is ₹5,987, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neuland Laboratories Limited right now?
The price sits above even our optimistic bull case (₹7,783). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹4,191 to ₹7,783) leaves room in how you read the outcome.
Where does the earnings growth of Neuland Laboratories Limited (NEULANDLAB) come from?
Earnings per share at Neuland Laboratories Limited grew +25.3 % a year from 2015 to 2026. Broken into its drivers: revenue per share +10.2 %, EBIT margin +6.4 %, tax rate +1.2 %, residual (interest, one-offs) +5.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Neuland Laboratories Limited
How large is the market capitalisation of Neuland Laboratories Limited (NEULANDLAB)?
The market capitalisation of Neuland Laboratories Limited is ₹276B (≈ $2.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neuland Laboratories Limited (NEULANDLAB)?
The price-to-sales ratio of Neuland Laboratories Limited is 9.95 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neuland Laboratories Limited (NEULANDLAB)?
Earnings per share at Neuland Laboratories Limited are ₹389.03 (price ÷ EPS = P/E 55.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Neuland Laboratories Limited (NEULANDLAB)?
The dividend yield of Neuland Laboratories Limited is 0.1% (payout 3.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Neuland Laboratories Limited (NEULANDLAB)?
The net margin of Neuland Laboratories Limited is 18.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neuland Laboratories Limited (NEULANDLAB)?
The return on equity (ROE) of Neuland Laboratories Limited is 15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neuland Laboratories Limited (NEULANDLAB)?
On an EBIT basis the return on assets of Neuland Laboratories Limited is 14.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neuland Laboratories Limited (NEULANDLAB)?
The operating margin of Neuland Laboratories Limited is 30.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neuland Laboratories Limited (NEULANDLAB)?
Revenue at Neuland Laboratories Limited is growing +119% versus a year earlier (3y avg +20.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neuland Laboratories Limited (NEULANDLAB)?
Earnings per share at Neuland Laboratories Limited are growing +963% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Neuland Laboratories Limited (NEULANDLAB) generate?
The free cash flow of Neuland Laboratories Limited is −₹589M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neuland Laboratories Limited (NEULANDLAB) hold?
Neuland Laboratories Limited holds more cash than debt, ₹537M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Neuland Laboratories Limited in the live analysis
One click puts Neuland Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
